Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

4.185 +0.075 (+1.82%)
Streaming Delayed Price Updated: 2:25 PM EDT, Apr 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Phathom Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Top movers in Tuesday's session
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
IHS Holding Posts Upbeat Earnings, Joins Tencent Music Entertainment, Elbit Systems And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Preview: Phathom Pharmaceuticals's Earnings
Via Benzinga
Recap: Phathom Pharmaceuticals Q3 Earnings
Via Benzinga
Phathom Pharmaceuticals Resubmits FDA Application For Acid Blocker, Raises $131M Via Equity
  
Via Benzinga
Earnings Scheduled For March 6, 2025
Via Benzinga
Analyst Expectations for Phathom Pharmaceuticals's Future
Via Benzinga
Where Phathom Pharmaceuticals Stands With Analysts
Via Benzinga
Top Biotech Short Squeeze Stocks
Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market. 
Via Talk Markets
Topics Stocks / Equities
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
These Are The Top 3 Most-Shorted Stocks In August 2024; Here’s Why
Short-squeeze opportunities are tough to find. Combine market timing with fundamentals for these stocks. 
Via Talk Markets
PHAT Stock Earnings: Phathom Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
PHAT stock results show that Phathom Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now
Each of the following seven heavily-shorted stocks may have what it takes to become one of the next big short squeeze stocks. 
Via InvestorPlace
Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
Though short squeezes are never guaranteed, these three potential short squeeze stocks could provide generous returns if bought right. 
Via InvestorPlace
The 3 Best Healthcare Stocks to Buy in May 2024
Healthcare firms can make large amounts of money, particularly in the U.S. Here are the three best healthcare stocks to buy now. 
Via InvestorPlace
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
PHAT stock results show that Phathom Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
PHAT stock results show that Phathom Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mostly lower, with the Nasdaq Composite falling more than 200 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
What's Going On With Phathom Pharmaceuticals Stock?
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) shares are trading higher Monday after the company announced FDA approval of its reformulated vo 
Via Benzinga
Exposures Product Safety
Cramer Likes This Industrial Stock: A 'Well-Run' Company Doing 'A Lot Of Good Things'
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended not buying ChargePoint Holdings, Inc. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
Via Benzinga
3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now
One of the safest sectors on the market is biotech. Here are three cheap biotech stocks to buy that are good options for investors. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2023
Via Benzinga
Insiders Buying Phathom Pharmaceuticals And 2 Other Stocks
Although US stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.